Muhlenkamp Fund (MUHLX)

52.60
Net Asset Value
-0.62%
1 Day
-4.73%
Year-to-Date
Overall Morningstar Rating
Large blend
Style or Category
No Load
Sales Expenses
1.27%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks to maximize total after-tax return to its shareholders through capital appreciation- and income from dividends and interest- consistent with reasonable risk. The fund principally invests in a diversified list of common stocks of companies of any capitalization- determined by the investment adviser to be highly profitable- yet undervalued. Muhlenkamp & Company- Inc. (the "Adviser") looks for companies the advisor believes to have above-average profitability- as measured by corporate return-on-equity- and that sell at below-average prices- as measured by price-to-earnings-ratios.

Performance

1 month-2.99% 3 years+0.23%
3 months-10.20% 5 years+4.95%
1 year+9.23% Since inception+8.80%
Data through --

Peer Comparisonvs. Large blend

 MUHLXCategory
Performance 5-yr return+4.95%+11.72%
Expense ratio1.27%0.97%
Risk 5 year sharpe ratio0.401.11
Net assets$235.0M$5.3B
Average market cap$33.9B$125.1B
Average P/E17.821.5
Portfolio turnover19%19%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyMuhlenkamp
Fund manager & tenureRonald Muhlenkamp / 29 Years
Minimal initial investment$1,500.00
Minimum IRA investment--

Holdings

U.S. stock83.64%
International stock10.26%
Fixed income3.23%
Cash2.86%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 28.02%
Telecommunication 15.23%
Consumer goods 12.73%
Consumer service 9.80%
Financial service 7.96%
Top 10 Holdings
Portfolio weighting
AAPL Apple8.17%
ON ON Semiconductor Corp6.75%
MSFT Microsoft6.57%
ADS Alliance Data Systems Corp5.37%
GILD Gilead Sciences4.95%
RUSHA Rush Enterprises Inc4.83%
UNH UnitedHealth3.98%
TCEHY Tencent3.90%
CE Celanese Corp3.62%
BMY Bristol-Myers Squibb3.53%